Can a statin boost liver cancer survival?
NCT ID NCT01903694
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding the cholesterol-lowering drug pravastatin to the standard cancer drug sorafenib helps people with advanced liver cancer live longer. It included 474 adults with Child-Pugh A cirrhosis whose cancer could not be cured. The main goal was to see if the combination improved overall survival compared to sorafenib alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHILD-PUGH A HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Dijon
Dijon, 21079, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.